| Website: http://www.maxim.com |
| Stock symbol: MAXM |
|
| Maxim Pharmaceuticals News (2003-2004) |
 |
| Wednesday, November 28, 2007 |
| SAN DIEGO--- Optimer Appoints Anthony E. Altig to Board of Directors Posted 8:16 AM PST |
| |
| SAN DIEGO--- Optimer Appoints Anthony E. Altig to Board of Directors Posted 8:38 AM PST |
| |
| Wednesday, October 31, 2007 |
| PASADENA--- Arrowhead Subs, Calando and Insert, Appoint Larry Stambaugh as CEO and President Posted 5:55 AM PST |
| |
| Tuesday, November 14, 2006 |
| SAN DIEGO--- Somaxon Pharmaceuticals Names Brian Dorsey Vice President of Manufacturing and Program Management Posted 6:10 AM PST |
| |
| Wednesday, June 14, 2006 |
| SAN DIEGO--- Optimer Pharmaceuticals Names John D. Prunty Chief Financial Officer Posted 6:28 AM PST |
| |
| Wednesday, December 21, 2005 |
| SAN DIEGO--- Stockholders of Maxim Pharmaceuticals Approve Merger Proposal Posted 4:19 PM PST |
| |
| Wednesday, December 14, 2005 |
| Maxim Pharmaceuticals Reports Fiscal 2005 Financial Results Posted 8:41 AM PST |
| |
| Thursday, December 8, 2005 |
| Maxim Pharmaceuticals Receives Recommendation from ISS in Favor of Proposed Merger with EpiCept Corporation Posted 9:05 AM PST |
| |
| Thursday, December 1, 2005 |
| Maxim Pharmaceuticals Mails Letter to Stockholders Reminding Them to Vote Their Proxies Posted 8:53 AM PST |
| |
| Monday, August 29, 2005 |
| Maxim Pharmaceuticals Apoptosis Research Discovery Published in PNAS Posted 9:49 AM PST |
| |
| Tuesday, August 2, 2005 |
| Maxim Pharmaceuticals Announces 2005 Third Quarter Financial Results Posted 9:45 AM PST |
| |
| Thursday, July 7, 2005 |
| Maxim Pharmaceuticals Announces Issue of U.S. Patent 6,906,203 Covering a Novel Class of Apoptosis Inducers Posted 9:09 AM PST |
| |
| Monday, May 2, 2005 |
| Maxim Pharmaceuticals Announces 2005 Second Quarter Financial Results Posted 9:17 AM PST |
| |
| Wednesday, April 27, 2005 |
| SAN DIEGO--- Maxim Pharmaceuticals Receives $1 Million Development Milestone Payment under Agreement with Myriad Genetics Posted 10:51 AM PST |
| |
| Tuesday, April 19, 2005 |
| Maxim Pharmaceuticals Issued Patent for Method of Identifying Therapeutically Effective Immunosupressive Agents Posted 10:22 AM PST |
| |
| Friday, April 15, 2005 |
| Maxim Pharmaceuticals Presents Discovery of Novel Apoptosis Target at AACR; Identification of TIP47, an IGFR II Binding Protein, as a Molecular Target for a Novel Class of Anticancer Agents Posted 6:03 AM PST |
| |
| Tuesday, April 12, 2005 |
| Maxim Announces Initiation of New Apoptosis Screening Campaign and Publication of Manuscript in Journal of Medicinal Chemistry Posted 9:44 AM PST |
| |
| Tuesday, March 15, 2005 |
| Maxim Pharmaceuticals Retains Piper Jaffray & Co. As Strategic Advisor Posted 7:29 AM PST |
| |
| Thursday, February 17, 2005 |
| Maxim Pharmaceuticals to Present at BIO CEO & Investor Conference 2005 Posted 12:06 PM PST |
| |
| Wednesday, February 2, 2005 |
| Maxim Pharmaceuticals Announces Fiscal 2005 First Quarter Financial Results Posted 11:24 AM PST |
| |
| Tuesday, January 18, 2005 |
| Maxim Reports That Additional Phase 3 Trial of Ceplene Therapy in the Treatment of Acute Myeloid Leukemia Patients in Complete Remission Will Be Required by the FDA Posted 9:52 AM PST |
| |
| Tuesday, August 3, 2004 |
| Maxim Pharmaceuticals Announces 2004 Third Quarter Financial Results Posted 9:45 AM PST |
| |
| Tuesday, July 27, 2004 |
| SAN DIEGO--- Maxim Pharmaceuticals Announces Appointment of Richard A. Mafrica as Vice President Commercialization Posted 8:49 AM PST |
| |
| Tuesday, June 29, 2004 |
| Maxim Pharmaceuticals Added to Russell 2000 Index Posted 7:44 AM PST |
| |
| Wednesday, June 2, 2004 |
| SAN FRANCISCO--- Biotech Loses Ground in May ... as the economy stalls and the IPO market softens Posted 8:58 AM PST |
| |
| Wednesday, May 12, 2004 |
| Maxim Pharmaceuticals Announces Phase 3 Trial of Ceplene in Acute Myeloid Leukemia Meets Primary Trial Endpoint Posted 8:29 AM PST |
| |
| Tuesday, May 4, 2004 |
| Maxim Pharmaceuticals Announces 2004 Second Quarter Financial Results Posted 9:14 AM PST |
| |
| Monday, April 19, 2004 |
| Maxim Pharmaceuticals Presents Preclinical Data on Histamine's Ability to Prevent Liver Damage Posted 8:43 AM PST |
| |
| Wednesday, April 14, 2004 |
| Maxim Pharmaceuticals Receives Approval from FDA of a Treatment Protocol for Ceplene-TM- in Advanced Malignant Melanoma Posted 9:52 AM PST |
| |
| Tuesday, March 30, 2004 |
| Maxim Pharmaceuticals Presents Preclinical Results for Its Novel Vascular Targeting Agent MX116407 Posted 8:33 AM PST |
| |
| Tuesday, March 23, 2004 |
| Maxim Pharmaceuticals Completes Phase 1 Pharmacokinetic Trial of Orally Dosed Histamine Posted 9:03 AM PST |
| |
| Wednesday, March 17, 2004 |
| Maxim Pharmaceuticals Reacquires Rights to MX2105 Preclinical Cancer Drug Candidate; Maxim Also Announces Two MX2105 Abstracts to Be Presented at AACR Posted 8:49 AM PST |
| |
| Thursday, February 12, 2004 |
| Maxim Pharmaceuticals Announces Publication of the Discovery and Characterization of Potent Anti-Cancer Compound Posted 9:22 AM PST |
| |
| Tuesday, February 3, 2004 |
| Maxim Pharmaceuticals Announces Fiscal 2004 First Quarter Financial Results Posted 9:17 AM PST |
| |
| Thursday, January 22, 2004 |
| Maxim Pharmaceuticals Discovers Potential Therapeutic Against the SARS Coronavirus Posted 9:25 AM PST |
| |
| Tuesday, January 20, 2004 |
| Maxim Pharmaceuticals Announces Release of Preclinical Results with Apoptosis Compound Showing Tumor Regression in Pancreatic Cancer Posted 8:36 AM PST |
| |
| Tuesday, December 16, 2003 |
| Maxim Pharmaceuticals Reports Fiscal 2003 Financial Results Posted 9:25 AM PST |
| |
| Monday, December 15, 2003 |
| Maxim Pharmaceuticals Awarded Most Innovative Product Award by UCSD Connect Posted 9:02 AM PST |
| |
| Wednesday, December 10, 2003 |
| SAN DIEGO--- UC San Diego CONNECT Announces Most Innovative New Product -MIP- Award Winners Posted 5:04 PM PST |
| |
| Tuesday, December 2, 2003 |
| Maxim Pharmaceuticals Licenses Novel Cancer Therapeutic Candidate to Myriad Genetics Posted 9:16 AM PST |
| |
| Friday, November 21, 2003 |
| Maxim Pharmaceuticals Presents Preclinical Results for MX2167 Novel Cancer Therapeutic Posted 8:51 AM PST |
| |
| Monday, November 17, 2003 |
| SAN DIEGO--- Maxim Pharmaceuticals Adds Wayne Yetter to Its Board of Directors; Maxim Expands Board of Directors With Addition of Former Novartis and Astra Merck Pharmaceutical Executive Posted 9:39 AM PST |
| |
| Wednesday, November 12, 2003 |
| Maxim Announces Publication of Research Results Supporting Use of Histamine in Treatment of Hepatitis C Posted 8:44 AM PST |
| |
| Friday, November 7, 2003 |
| Maxim Files for European Approval to Market Ceplene for the Treatment of Advanced Malignant Melanoma Posted 8:22 AM PST |
| |
| Thursday, October 30, 2003 |
| Gen-Probe Reports Third Quarter 2003 Financial Results Posted 3:21 PM PST |
| |
| Tuesday, October 28, 2003 |
| Maxim Pharmaceuticals Presents Preclinical Data on Liver Regeneration Posted 8:54 AM PST |
| |
| Wednesday, October 1, 2003 |
| Maxim Announces Preclinical Study Showing Synergy of Ceplene and Chemotherapy in Cancer Treatment Posted 7:14 AM PST |
| |
| Wednesday, September 24, 2003 |
| Maxim Pharmaceuticals Completes Enrollment of Advanced Malignant Melanoma Phase 3 Clinical Trial Posted 7:15 PM PST |
| |
| Tuesday, September 23, 2003 |
| Maxim Pharmaceuticals Announces $25.5 Million Private Placement Posted 8:20 AM PST |
| |
| SAN DIEGO--- Maxim Pharmaceuticals Announces $25.5 Million Private Placement Posted 8:21 AM PST |
| |
| Thursday, June 12, 2003 |
| Maxim Pharmaceuticals Announces Publication of Ceplene Phase 3 Quality of Life Results in Supportive Care in Cancer Posted 8:08 AM PST |
| |
| Tuesday, May 6, 2003 |
| Maxim Pharmaceuticals Announces 2003 Second Quarter Financial Results Posted 8:04 AM PST |
| |
| Wednesday, April 23, 2003 |
| Maxim Files U.S. Patent Applications Encompassing the Discovery of Two Novel Targets for Cancer Treatment Posted 7:54 AM PST |
| |
| Wednesday, April 16, 2003 |
| Maxim Apoptosis Drug Candidates Show Anti-Tumor Activity in Breast and Colorectal Cancer Preclinical Studies Posted 7:34 AM PST |
| |
| Thursday, March 13, 2003 |
| Maxim Pharmaceuticals Receives Phase 2 SBIR Grant from National Cancer Institute for Testing of Lead Apoptosis Anti-Cancer Agent Posted 4:58 PM PST |
| |
| Thursday, February 6, 2003 |
| SAN DIEGO--- Maxim Pharmaceuticals Announces New Scientific and Development Advisory Board Posted 8:06 AM PST |
| |
| Tuesday, February 4, 2003 |
| Maxim Pharmaceuticals Announces 2003 First Quarter Financial Results Posted 8:39 AM PST |
| |
| Wednesday, January 22, 2003 |
| SAN DIEGO--- Maxim Pharmaceuticals Adds New Head of Regulatory Affairs Team Posted 9:43 AM PST |
| |
| Tuesday, January 14, 2003 |
| SAN DIEGO--- Maxim Pharmaceuticals Announces Robert L. Zerbe Nominated to Its Board of Directors Posted 7:46 AM PST |
| |
